Tags

Type your tag names separated by a space and hit enter

Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Clin Exp Dermatol. 2021 Jul; 46(5):820-824.CE

Abstract

Atopic dermatitis (AD) is chronic, pruritic, inflammatory skin disease that affects a significant portion of the population in industrialized nations. For nonresponders to conventional therapies, AD can significantly reduce sleep quality and quality of life. AD pathogenesis is multifactorial and involves multiple immune pathways, with recent evidence of T helper (Th)2, Th17 and Th22 axis attenuation in various AD endotypes and racial subtypes. Inhibition of the conserved Janus kinase (JAK) signalling pathway represents a promising therapeutic avenue to reduce the activation of multiple proinflammatory mediators involved in AD pathogenesis. JAK inhibitors exist in both oral and topical forms with variable specificity for the receptor tyrosine kinases JAK1, JAK2, JAK3 and tyrosine kinase 2. Oral formulations include abrocitinib, upadacitinib, baricitinib and gusacitinib, and are most appropriate for patients with moderate to severe AD. Emerging topical formulation in development include ruxolitinib and deglocitinib, which may be used in patients with localized AD and also adjunctively with systemic therapy in patients with more severe disease. With observed rapidity in itch relief and accompanying dramatic reduction in inflammatory lesion count, JAK inhibitors represent a promising new treatment to revolutionize the management of AD.

Authors+Show Affiliations

Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD, USA.Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD, USA.Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA.Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33484582

Citation

Cartron, A M., et al. "Janus Kinase Inhibitors for Atopic Dermatitis: a Promising Treatment Modality." Clinical and Experimental Dermatology, vol. 46, no. 5, 2021, pp. 820-824.
Cartron AM, Nguyen TH, Roh YS, et al. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. Clin Exp Dermatol. 2021;46(5):820-824.
Cartron, A. M., Nguyen, T. H., Roh, Y. S., Kwatra, M. M., & Kwatra, S. G. (2021). Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. Clinical and Experimental Dermatology, 46(5), 820-824. https://doi.org/10.1111/ced.14567
Cartron AM, et al. Janus Kinase Inhibitors for Atopic Dermatitis: a Promising Treatment Modality. Clin Exp Dermatol. 2021;46(5):820-824. PubMed PMID: 33484582.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Janus kinase inhibitors for atopic dermatitis: a promising treatment modality. AU - Cartron,A M, AU - Nguyen,T H, AU - Roh,Y S, AU - Kwatra,M M, AU - Kwatra,S G, Y1 - 2021/02/28/ PY - 2021/01/21/accepted PY - 2021/1/24/pubmed PY - 2021/11/30/medline PY - 2021/1/23/entrez SP - 820 EP - 824 JF - Clinical and experimental dermatology JO - Clin Exp Dermatol VL - 46 IS - 5 N2 - Atopic dermatitis (AD) is chronic, pruritic, inflammatory skin disease that affects a significant portion of the population in industrialized nations. For nonresponders to conventional therapies, AD can significantly reduce sleep quality and quality of life. AD pathogenesis is multifactorial and involves multiple immune pathways, with recent evidence of T helper (Th)2, Th17 and Th22 axis attenuation in various AD endotypes and racial subtypes. Inhibition of the conserved Janus kinase (JAK) signalling pathway represents a promising therapeutic avenue to reduce the activation of multiple proinflammatory mediators involved in AD pathogenesis. JAK inhibitors exist in both oral and topical forms with variable specificity for the receptor tyrosine kinases JAK1, JAK2, JAK3 and tyrosine kinase 2. Oral formulations include abrocitinib, upadacitinib, baricitinib and gusacitinib, and are most appropriate for patients with moderate to severe AD. Emerging topical formulation in development include ruxolitinib and deglocitinib, which may be used in patients with localized AD and also adjunctively with systemic therapy in patients with more severe disease. With observed rapidity in itch relief and accompanying dramatic reduction in inflammatory lesion count, JAK inhibitors represent a promising new treatment to revolutionize the management of AD. SN - 1365-2230 UR - https://www.unboundmedicine.com/medline/citation/33484582/Janus_kinase_inhibitors_for_atopic_dermatitis:_a_promising_treatment_modality_ L2 - https://doi.org/10.1111/ced.14567 DB - PRIME DP - Unbound Medicine ER -